Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

combination with other approved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits Aurora A selectively, it also inhibits a cluster of kinases that are important for tumor growth, particularly growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity in multiple preclinical models, including both solid tumors and hematological cancers."

James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... (NASDAQ: GPRO ) announced today that the Company ... April 28, 2011 at approximately 4:00 pm Eastern Time (ET). ... management at 4:30 pm ET.   The conference ... the investors section of the Company,s web site at ...
... Proteon Therapeutics, Inc. has initiated enrollment in a ... in chronic kidney disease (CKD) patients undergoing surgery for ... study follows successful completion of a 66-patient, double-blind, placebo-controlled ... completed enrollment in July 2010. "Our lead ...
... Texas, April 14, 2011 The Wound Institute today ... dynamic reciprocity at the combined meeting of the Symposium ... Society (WHS) being held in Dallas at the Gaylord ... Presenting faculty are Dr. Ira M. Herman, tenured Professor ...
Cached Biology Technology:Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call 2Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 4
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... A team of Dutch researchers under the leadership of ... They weakened fear memories in human volunteers by administering ... return over the course of time. Top journal ... 2009. Until recently, it was assumed that ...
... CO More than 300 geoscientists will gather 12-13 ... Section of the Geological Society of America. The meeting ... in St. Petersburg, Florida. , Geoscientists from the University ... the meeting along with the USF Geology Alumni Society. ...
... much salt, and a University of Iowa researcher has discovered ... in a better mood. UI psychologist Kim Johnson and ... in sodium chloride, common table salt, they shy away from ... pressing a bar that stimulates a pleasant sensation in their ...
Cached Biology News:An end to fear 2Study suggests salt might be 'nature's antidepressant' 2Study suggests salt might be 'nature's antidepressant' 3
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
...
... Corning CellBIND surface is produced by a ... hydrophilic surface giving more consistent, even cell ... enhances cell attachment and growth uunder difficult ... • CellBIND may provide a more ecominic ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Biology Products: